BIP Trial: Difference between revisions
| Line 7: | Line 7: | ||
===Methods=== | ===Methods=== | ||
This is a double-blinded study where 3090 patients with a previous myocardial infarction or stable angina with a total cholesterol of 180 - 250 mg/dL, HDL- | This is a double-blinded study where 3090 patients with a previous myocardial infarction or stable angina with a total cholesterol of 180 - 250 mg/dL, HDL-C≤45 mg/dL, triglycerides≤300 mg/dL, and low-density lipoprotein cholesterol≤180 mg/dL were randomized to receive either 400 mg of bezafibrate per day or a placebo; they were followed for a mean of 6.2 years. fatal or nonfatal myocardial infarction or sudden death were the primary outcomes considered. | ||
==Results== | ==Results== | ||
* 18% increase in HDL-C and a 21% reduction observed in triglycerides. | * 18% increase in HDL-C and a 21% reduction observed in triglycerides. | ||
Revision as of 11:30, 18 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
BIP Trial On the Web |
|
American Roentgen Ray Society Images of BIP Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To determine the safety and efficacy of bezafibrate in raising HDL cholesterol and lowering triglycerides in patients with coronary artery disease.
Methods
This is a double-blinded study where 3090 patients with a previous myocardial infarction or stable angina with a total cholesterol of 180 - 250 mg/dL, HDL-C≤45 mg/dL, triglycerides≤300 mg/dL, and low-density lipoprotein cholesterol≤180 mg/dL were randomized to receive either 400 mg of bezafibrate per day or a placebo; they were followed for a mean of 6.2 years. fatal or nonfatal myocardial infarction or sudden death were the primary outcomes considered.
Results
- 18% increase in HDL-C and a 21% reduction observed in triglycerides.
- The reduction in the cumulative probability of the primary end point was 7.3%, (P=0.24) after 6.2 years.
- Post hoc analysis in the group of patients with high baseline triglycerides (> or =200 mg/dL) revealed a reduction by 39.5% (P=0.02) in the cumulative probability of the primary end point.
- Total and noncardiac mortality, adverse events and cancer were equally distributed between the two groups.
Conclusion
Bezafibrate was safe and effective in elevating HDL-C levels and lowering triglycerides. A reduction of the incidence of primary end points was also observed.